[go: up one dir, main page]

MX2011010918A - Metodo para el tratamiento de trastornos asociados con la actividad de la cinasa de proteina ck2. - Google Patents

Metodo para el tratamiento de trastornos asociados con la actividad de la cinasa de proteina ck2.

Info

Publication number
MX2011010918A
MX2011010918A MX2011010918A MX2011010918A MX2011010918A MX 2011010918 A MX2011010918 A MX 2011010918A MX 2011010918 A MX2011010918 A MX 2011010918A MX 2011010918 A MX2011010918 A MX 2011010918A MX 2011010918 A MX2011010918 A MX 2011010918A
Authority
MX
Mexico
Prior art keywords
sup
protein kinase
disorders associated
activity
treating disorders
Prior art date
Application number
MX2011010918A
Other languages
English (en)
Inventor
Mustapha Haddach
Kenna Anderes
Sean O'brien
Original Assignee
Cylene Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cylene Pharmaceuticals Inc filed Critical Cylene Pharmaceuticals Inc
Publication of MX2011010918A publication Critical patent/MX2011010918A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • AIDS & HIV (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)

Abstract

La invención proporciona métodos para el tratamiento de trastornos asociados con la actividad no deseada de la cinasa de proteína CK2, utilizando compuestos de la fórmula (I) que son inhibidores potentes y selectivos de CK2, y composiciones farmacéuticas de dichos compuestos, en donde Z5, R6B, R6D, R8, n, R9 y p se definen como se describe adicionalmente aquí.
MX2011010918A 2009-04-17 2010-04-16 Metodo para el tratamiento de trastornos asociados con la actividad de la cinasa de proteina ck2. MX2011010918A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US17046809P 2009-04-17 2009-04-17
US24016509P 2009-09-04 2009-09-04
US24222709P 2009-09-14 2009-09-14
US29766910P 2010-01-22 2010-01-22
PCT/US2010/031520 WO2010121225A2 (en) 2009-04-17 2010-04-16 Method of treating disorders associated with protein kinase ck2 activity

Publications (1)

Publication Number Publication Date
MX2011010918A true MX2011010918A (es) 2012-02-29

Family

ID=42981447

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011010918A MX2011010918A (es) 2009-04-17 2010-04-16 Metodo para el tratamiento de trastornos asociados con la actividad de la cinasa de proteina ck2.

Country Status (14)

Country Link
US (1) US20100267753A1 (es)
EP (1) EP2419101A2 (es)
JP (1) JP2012524076A (es)
KR (1) KR20120044281A (es)
CN (1) CN102481289A (es)
AU (1) AU2010236162A1 (es)
BR (1) BRPI1016185A2 (es)
CA (1) CA2758974A1 (es)
IL (1) IL215712A0 (es)
MX (1) MX2011010918A (es)
RU (1) RU2011146544A (es)
SG (1) SG175210A1 (es)
WO (1) WO2010121225A2 (es)
ZA (1) ZA201107773B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2767273A1 (en) * 2013-02-15 2014-08-20 Universitätsklinikum Erlangen Death-associated protein kinases, inhibitors and activators thereof for use in pharmaceutical compositions and in predictive medicine
CN105457029A (zh) * 2014-09-29 2016-04-06 中国科学院上海巴斯德研究所 抑制酪蛋白激酶2活性在促进i型干扰素表达的应用
ES2926012T3 (es) * 2016-05-20 2022-10-21 Inst Nat Sante Rech Med Métodos y composiciones farmacéuticas para el tratamiento de desregulaciones del microbioma asociadas con la interrupción del reloj circadiano
US20200009134A1 (en) * 2017-03-03 2020-01-09 Gritscience Biopharmaceuticals Co., Ltd. Method and Compound for Modifying Circadian Clock
CN111447931B (zh) * 2017-07-31 2024-01-26 加利福尼亚大学董事会 抗癌/抗纤维化化合物
IL275489B2 (en) 2017-12-22 2024-06-01 Ravenna Pharmaceuticals Inc Chromenopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors
TW202112784A (zh) 2019-06-17 2021-04-01 美商佩特拉製藥公司 作為磷脂酸肌醇磷酸激酶抑制劑之𠳭唏并嘧啶衍生物
CN113444084A (zh) * 2020-03-26 2021-09-28 东南大学 一类抗肿瘤化合物及其制备与用途
CA3179372A1 (en) * 2020-03-30 2021-10-07 Senhwa Biosciences, Inc. Antiviral compounds and method for treating hepatotropic viral infection, particularly hepatitis b and hepatitis d
CN112274642A (zh) * 2020-10-15 2021-01-29 北京大学人民医院 Ck2抑制剂在制备类风湿关节炎治疗药物中的应用
WO2023126951A1 (en) * 2022-01-03 2023-07-06 Yeda Research And Development Co. Ltd. Inhibitors of autophagy-related protein-protein interactions
CN114957252B (zh) * 2022-07-14 2023-09-05 苏州施安鼎泰生物医药技术有限公司 一种化合物及其制备方法以及药物组合物和在制备eed抑制剂中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2724B1 (en) * 2004-08-19 2013-09-15 افينتس فارماسوتيكالز انك 3-Alternative-5 -6-Amino Alkyl Indole-2-Carboxyl Acid Amide and Related Isotopes as Casein Kinase Inhibitors
ES2528316T3 (es) * 2006-09-01 2015-02-06 Senhwa Biosciences, Inc. Moduladores de la serina-treonina proteína quinasa y de PARP
JP2011515337A (ja) * 2008-02-29 2011-05-19 サイレーン ファーマシューティカルズ， インコーポレイテッド プロテインキナーゼモジュレーター

Also Published As

Publication number Publication date
BRPI1016185A2 (pt) 2016-04-19
EP2419101A2 (en) 2012-02-22
RU2011146544A (ru) 2013-05-27
SG175210A1 (en) 2011-11-28
CA2758974A1 (en) 2010-10-21
WO2010121225A2 (en) 2010-10-21
IL215712A0 (en) 2012-01-31
JP2012524076A (ja) 2012-10-11
AU2010236162A1 (en) 2011-11-03
WO2010121225A3 (en) 2011-01-06
ZA201107773B (en) 2012-07-25
US20100267753A1 (en) 2010-10-21
KR20120044281A (ko) 2012-05-07
CN102481289A (zh) 2012-05-30

Similar Documents

Publication Publication Date Title
MX2011010918A (es) Metodo para el tratamiento de trastornos asociados con la actividad de la cinasa de proteina ck2.
AU2018236800B2 (en) DNA-PK inhibitors
MX2013012776A (es) Inhibidores de la tirosina cinasa de bazo que contienen aminopiridina.
UA99882C2 (uk) Похідні бензофуранілу, фармацевтична композиція та спосіб лікування захворювань (варіанти)
MX2009009592A (es) Aminopiridinas utiles como inhibidores de proteinas cinasas.
MX2009008253A (es) Derivados de 2-aminopiridina utiles como inhibidores de cinasa.
IN2014KN00929A (es)
MY199894A (en) Prmt5 inhibitors and uses thereof
TN2009000128A1 (en) Dihydropyridine derivatives useful as protein kinase inhibitors
EA200900983A1 (ru) Соединения и композиции в качестве ингибиторов киназы
UA95644C2 (ru) Пиридазиноновые производные, фармацевтическая композиция и способ лечения заболеваний
EA200970447A1 (ru) Соединения и композиции в качестве ингибиторов протеинкиназы
MX2009006345A (es) Compuestos utiles como inhibidores de proteina cinasa.
MX2009011211A (es) Indoles sustituidos en la posicion 7 inhibidores de mci-1.
NO20083918L (no) Dihydridiazepiner anvendelige som inhibitorer av proteinkinaser
MX2012000709A (es) Inhibidores de pirrolopiridina de cinasas.
IL200793A0 (en) Aminopyrimidines, compositions comprising the same and use thereof for inhibiting protein kinases
NO20084747L (no) Tetrahydropteridiner anvendbare som inhibitorer av protein kinaser
MX2009010207A (es) Peptidos de hidrazido como inhibidores de proteasa ns3 de virus de hepatitis c.
EA201100748A1 (ru) Пиразиновые соединения в качестве ингибиторов фосфодиэстеразы 10
MX2009011810A (es) Tiazoles y pirazoles utiles como inhibidores de cinasa.
WO2010083207A3 (en) Protein kinase c inhibitors and uses thereof
MX2009012719A (es) Tiazoles y pirazoles utiles como inhibidores de cinasa.
NO20090608L (no) Tyrosinkinaseinhibitorer
MX336711B (es) Inhibidores de catecol o-metil transferasa y su uso en el tratamiento de transtornos psicoticos.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal